Statin-associated myopathy: From genetic predisposition to clinical management

Physiological Research

Volumn 63, Issue , 2014, Pages S327-S334

  Vrablik, M ^a   Zlatohlavek, L ^a   Stulc, T ^a   Adamkova, V ^b   Prusikova, M ^a   Schwarzova, L ^a   Hubacek, J A ^b   Ceska, R ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Definition; Genetics; Risk score; Statin associated myopathy; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL; CHEMICALLY INDUCED; DISEASE MANAGEMENT; GENETIC PREDISPOSITION; GENETICS; HUMAN; MUSCULAR DISEASES; RISK FACTOR;

ANIMALS; DISEASE MANAGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; RISK FACTORS;

EID: 84920988942     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. ABD TT, JACOBSON TA: Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10: 373-387, 2011.
2. BECKER ML, VISSER LE, VAN SCHAIK RH, HOFMAN A, UITTERLINDEN AG, STRICKER BH: Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol Drug Saf 19: 75-81, 2010.
3. BRUNHAM LR, LANSBERG PJ, ZHANG L, MIAO F, CARTER C, HOVINGH GK, VISSCHER H, JUKEMA JW, STALENHOEF AF, ROSS CJ, CARLETON BC, KASTELEIN JJ, HAYDEN MR: Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 12: 233-237, 2012.
4. CATAPANO AL, REINER Z, DE BACKER G, GRAHAM I, TASKINEN MR, WIKLUND O, AGEWALL S, ALEGRIA E, CHAPMAN M, DURRINGTON P, ERDINE S, HALCOX J, HOBBS R, KJEKSHUS J, FILARDI PP, RICCARDI G, STOREY RF, WOOD D; EUROPEAN SOCIETY OF CARDIOLOGY (ESC); EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS): ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217: 3-46, 2011.
5. CARR DF, O'MEARA H, JORGENSEN AL, CAMPBELL J, HOBBS M, MCCANN G, VAN STAA T, PIRMOHAMED M: SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 94: 695-701, 2013.
6. DANIK JS, CHASMAN DI, MACFADYEN JG, NYBERG F, BARRATT BJ, RIDKER PM: Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J 165: 1008-1014, 2013.
7. DONNELLY LA, DONEY AS, TAVENDALE R, LANG CC, PEARSON ER, COLHOUN HM, MCCARTHY MI, HATTERSLEY AT, MORRIS AD, PALMER CN: Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 89: 210-216, 2011.
8. DOSEDEL M, MALY J, VLCEK J: Drug interactions with statins and their clinical severity and management. Remedia 21: 392-397, 2011.
9. EISEN A, LEV E, IAKOBISHVILLI Z, PORTER A, BROSH D, HASDAI D, MAGER A: Low plasma vitamin D levels and muscle-related adverse effects in statin users. Isr Med Assoc J 16: 42-45, 2014.
10. EMMANUELE V, LÓPEZ LC, BERARDO A, NAINI A, TADESSE S, WEN B, D'AGOSTINO E, SOLOMON M, DIMAURO S, QUINZII C, HIRANO M: Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol 69: 978-983, 2012.
11. FRUDAKIS TN, THOMAS MJ, GINJUPALLI SN, HANDELIN B, GABRIEL R, GOMEZ HJ: CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet Genomics 17: 695-707, 2007.
12. FURIHATA T, SATOH N, OHISHI T, UGAJIN M, KAMEYAMA Y, MORIMOTO K, MATSUMOTO S, YAMASHITA K, KOBAYASHI K, CHIBA K: Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. Pharmacogenomics J 9: 185-193, 2009.
13. GHATAK A, FAHEEM O, THOMPSON PD: The genetics of statin-induced myopathy. Atherosclerosis 210: 337-343, 2010.
14. GLUECK CJ, BUDHANI SB, MASINENI SS, ABUCHAIBE C, KHAN N, WANG P, GOLDENBERG N: Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 27: 1683-1690, 2011.
15. GRIFFIN JP: The withdrawal of Baycol (cerivastatin). Adverse Drug React Toxicol Rev 20: 177-180, 2001.
16. GUPTA A, THOMPSON PD: The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 215: 23-29, 2011.
17. HANSEN KE, HILDEBRAND JP, FERGUSON EE, STEIN JH: Outcomes in 45 patients with statin-associated myopathy. Ann Intern Med 165: 2671-2676, 2005.
18. HUBACEK JA: Drug metabolising enzyme polymorphisms in Middle- and Eastern-European Slavic populations. Drug Metabol Drug Interact 29: 29-36, 2014.
19. HUBACEK JA, VRABLIK M: Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact 26: 13-20, 2011.
20. HUBACEK JA, DLOUHA D, ADÁMKOVA V, LANSKA V, CESKA R, VRABLIK M: Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. Neuro Endocrinol Lett 33 (Suppl 2): 22-25, 2012.
21. KAMAL-BAHL SJ, BURKE T, WATSON D, WENTWORTH C: Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 99: 530-534, 2007.
22. KRISHNAN GM, THOMPSON PD: The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol 21: 324-328, 2010.
23. LEISERSON MD, ELDRIDGE JV, RAMACHANDRAN S, RAPHAEL BJ: Network analysis of GWAS data. Curr Opin Genet Dev 23: 602-610, 2013.
24. MARCIANTE KD, DURDA JP, HECKBERT SR, LUMLEY T, RICE K, MCKNIGHT B, TOTAH RA, TAMRAZ B, KROETZ DL, FUKUSHIMA H, KASPERA R, BIS JC, GLAZER NL, LI G, AUSTIN TR, TAYLOR KD, ROTTER JI, JAQUISH CE, KWOK PY, TRACY RP, PSATY BM: Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 21: 280-288, 2011.
25. MCKENNEY JM, DAVIDSON MH, JACOBSON TA, JACOBSON TA, GUYTON JR: Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97: 89C-94C, 2006.
26. MIKUS CR, BOYLE LJ, BORENGASSER SJ, OBERLIN DJ, NAPLES SP, FLETCHER J, MEERS GM, RUEBEL M, LAUGHLIN MH, DELLSPERGER KC, FADEL PJ, THYFAULT JP: Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 62: 709-714, 2013.
27. NEEDHAM M, MASTAGLIA FL: Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 24: 4-15, 2014.
28. NEWMAN C, TSAI J, SZAREK M, LUO D, GIBSON E: Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97: 61-67, 2006.
29. NIEMI M, PASANEN MK, NEUVONEN PJ: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 80: 356-366, 2006.
30. NIEMI M, PASANEN MK, NEUVONEN PJ: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 63: 157-181, 2011.
31. OH J, BAN MR, MISKIE BA, POLLEX RL, HEGELE RA: Genetic determinants of statin intolerance. Lipids Health Dis 6: 7, 2007.
32. PARKER BA, AUGERI AL, CAPIZZI JA, BALLARD KD, TROYANOS C, BAGGISH AL, D'HEMECOURT PA, THOMPSON PD: Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol 109: 282-287, 2012.
33. PARKER BA, CAPIZZI JA, GRIMALDI AS, CLARKSON PM, COLE SM, KEADLE J, CHIPKIN S, PESCATELLO LS, SIMPSON K, WHITE CM, THOMPSON PD: Effect of statins on skeletal muscle function. Circulation 127: 96-103, 2013.
34. PASANEN MK, NEUVONEN M, NEUVONEN PJ, NIEMI M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16: 873-879, 2006.
35. PASANEN MK, FREDRIKSON H, NEUVONEN PJ, NIEMI M: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82: 726-733, 2007.
36. PASANEN MK, MIETTINEN TA, GYLLING H, NEUVONEN PJ, NIEMI M: Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenet Genomics 18: 921-926, 2008.
37. PREMRU V, KOVAČ J, PONIKVAR R: Use of myoglobin as a marker and predictor in myoglobinuric acute kidney injury. Ther Apher Dial 17: 391-395, 2013.
38. RAJU SB, VARGHESE K, MADHU K: Management of statin intolerance. Indian J Endocrinol Metab 17: 977-982, 2013.
39. ROBINSON MR, WRAY NR, VISSCHER PM: Explaining additional genetic variantion in complex traits. Trends Genet 30: 124-132, 2014.
40. SEARCH COLLABORATIVE GROUP, LINK E, PARISH S, ARMITAGE J, BOWMAN L, HEATH S, MATSUDA F, GUT I, LATHROP M, COLLINS R: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 359: 789-799, 2008.
41. SEMPLE SJ: Statin therapy, myopathy and exercise - a case report. Lipids Health Dis 11: 40, 2012.
42. STEWART A: SLCO1B1 polymorphisms and statin-indused myopathy. PloS Curr Evidence on Genomic Tests 1: doi: 10.1371/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203, 2013.
43. VOORA D, SHAH SH, SPASOJEVIC I, ALI S, REED CR, SALISBURY BA, GINSBURG GS: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54: 1609-1616, 2009.
44. YOUNG JM, FLORKOWSKI CM, MOLYNEUX SL, MCEWAN RG, FRAMPTON CM, GEORGE PM, SCOTT RS: Effect of coenzyme Q (10) supplementation on simvastatin-induced myalgia. Am J Cardiol 100: 1400-1403, 2007.
45. ZLATOHLAVEK L, VRABLIK M, GRAUOVA B, MOTYKOVA E, CESKA R: The effect of coenzyme Q10 in statin myopathy. Neuro Endocrinol Lett 33 (Suppl 2): 98-101, 2012.
46. ZUCCARO P, MOMBELLI G, CALABRESI L, BALDASSARE D, PALMI I, SIRTORI CR: Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res 55: 310-317, 2007.